Total Sample | Females | Males | |||||||
---|---|---|---|---|---|---|---|---|---|
Cases (n = 868) | Controls (n = 935) | Adjusted OR1 (95% CI) | Cases (n = 335) | Controls (n = 358) | Adjusted OR1 (95% CI) | Cases (n = 533) | Controls (n = 577) | Adjusted OR1 (95% CI) | |
Non-User | 747 | 768 | 1.0 | 299 | 306 | 1.0 | 448 | 462 | 1.0 |
Regular User2 | 121 | 167 | 0.57 (0.41–0.78) | 36 | 52 | 0.52 (0.29–0.95) | 85 | 115 | 0.62 (0.43–0.90) |
1–6 tablets/week | 26 | 41 | 0.53 (0.28–0.99) | 9 | 26 | 0.17 (0.05–0.50) | 17 | 15 | 1.01 (0.46–2.59) |
7+ tablets/week | 95 | 126 | 0.58 (0.41–0.82) | 27 | 26 | 0.88 (0.43–1.79) | 68 | 100 | 0.56 (0.37–0.83) |
p = 0.04 | p = 0.19 | p = 0.006 | |||||||
1–10 years of use | 90 | 126 | 0.56 (0.39–0.79) | 23 | 38 | 0.42 (0.21–0.86) | 67 | 88 | 0.65 (0.43–0.98) |
11+ years of use | 31 | 41 | 0.61 (0.34–1.09) | 13 | 14 | 0.88 (0.30–2.55) | 18 | 27 | 0.53 (0.26–1.10) |
p = 0.06 | p = 0.11 | p = 0.01 | |||||||
1–10 tablet years3 | 84 | 106 | 0.63 (0.44–0.92) | 20 | 30 | 0.47 (0.22–0.99) | 64 | 76 | 0.73 (0.48–1.12) |
11+ tablet years | 37 | 61 | 0.45 (0.27–0.77) | 16 | 22 | 0.61 (0.24–1.54) | 21 | 39 | 0.40 (0.21–0.78) |
p < 0.001 | p = 0.07 | p = 0.004 |